

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/643,888
Applicant : Don J. DIAMOND
Filed : August 20, 2003

TC/A.U. : 1642

Examiner : Not Yet Assigned

Docket No. : 1954-433 Customer No. : 06449 Confirmation No. : 4642

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449.

Respectfully submitted,

By

Martha Cassidy

Attorney for Applicants Registration No. 44,066

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

Enclosure

1954-433.IDS.wpd

| OLDE | war in | | <u>. </u> | T | Complete if Known | |
|------------------------|--------------|---|--|-------------------------------------|---|----------------|
| INFORMATION DISCLOSURE | | | | Application Number 10/643,888 | | |
| | | | | Filing Date | August 20, 2003 | |
| Sheet 1 of 1 | | | ANT | First Named Inventor | Don J. DIAMOND | |
| | | | | Group Art Unit | 1642 | |
| | | | | Examiner Name | Not Yet Assigned | |
| | | | 1 | Attorney Docket Number 1954-433 | | <u>.</u> |
| | | | NON PA | TENT LITERATURE DOCU | MENTS | |
| Examiner Initials* | Cite No.1 | Include na item (book, | ame of the au | thor (in CAPITAL LETTERS), title of | of the article (when appropriate), title of the etc.), date, page(s), volume-issue number(s), | T ² |
| | СС | Altman, John D., et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," Science 274:94-96, October 4, 1996. | | | | |
| | CD | Boppana, Suresh B., et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells," <i>Virology</i> 222 (Article 0424):293-296, 1996. | | | | |
| | CE | BenMohamed, Lbachir, <i>et al.</i> , "Induction of CTL Response by a Minimal Epitope Vaccine in HLA A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted T _H Response," <i>Human Immunology</i> 61:764-779, 2000. | | | | |
| | CF | Clave, Emmanuel, et al., "Use of a CMV pp65-Specific HLA Tetramer to Select and Expand CMV-Specific CD8+ CTL," Abstract #679, Post Board #-Session 679-1, Blood 94 (10 Suppl. 1):155a, November 15, 1999. | | | | |
| | CG | LaRosa, C., et al., "Development of In Vitro Stimulation (IVS) Protocol to Measure CMV Specific CTL Activity Using HLA-Restricted Specific CTL Epitopes," Abstract #2129, Blood 92 (10 Suppl. 1):518a, 1998. | | | | |
| | СН | Pande, Hema, et al., "Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus," Proc. Natl. Acad. Sci USA 81: 4965-4969, August 1984. | | | | |
| | CI | Schulz, Manfred, et al., "Peptide-induced antiviral protection by cytotoxic T Cells," Proc. Natl. Acad. Sci, USA Vol. 88: 991-993, February 1991. | | | | |
| | CJ | Spaete, Richard R., et al., "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage," Virology 167:207-225, 1988. | | | | |
| | СК | John A. Zaia et al., "Status of Cytomegalovirus Prevention and Treatment in 2000," Hematology:339-355, 2000. | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Examiner Signature | | | | | Date Considered | <u> </u> |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.